Literature DB >> 20840848

Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition.

Jennifer E Jahn1, D Hunter Best, William B Coleman.   

Abstract

The molecular pathogenesis of hepatocellular carcinoma is well-studied but not completely understood. We utilized a microcell-hybrid model of tumor suppression in rat liver tumor cells to facilitate the identification of liver tumor suppressor genes located on human chromosome 11. These investigations confirmed a liver tumor suppressor locus at human 11p11.2, identified Wt1 as a potential effector of 11p11.2-mediated tumor suppression, and subsequently identified human SYT13 as a strong candidate for the 11p11.2 liver tumor suppressor gene. In the studies presented here, we introduced SYT13 into the GN6TF rat liver tumor cell line to characterize a functional role for SYT13 in this model system. Transfected clones expressing an SDS-resistant dimer form of the SYT13 protein displayed induction of Wt1 gene expression and a significant attenuation of the neoplastic phenotype exhibited by the parental tumor cell line. Saturation densities and anchorage-independent growth of SYT13 dimer-positive cell lines were reduced in vitro, and tumorigenicity was significantly decreased or ablated in syngeneic host rats in vivo. In addition, restoration of the contact-inhibited, epithelioid morphology observed in normal liver epithelial cells accompanied ectopic expression of the SYT13 protein dimer, suggesting that SYT13 may be mediating an epithelial differentiation coordinate with tumor suppression in these cells. Accordingly, the expression of E-cadherin (Cdh1) mRNA was increased >100-fold in SYT13-dimer-positive cell lines and the Cdh1 transcriptional repressor Snail was decreased >3-fold in these cells compared to the parental tumor cells. These studies combine to suggest that SYT13 is a liver tumor suppressor gene and that its function may be mediated through pathways implicated in mesenchymal to epithelial transition.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840848     DOI: 10.1016/j.yexmp.2010.09.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  5 in total

1.  Synaptotagmin 11 scaffolds MKK7-JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis.

Authors:  Bo-Kyung Kim; Da-Mi Kim; Hyunkyung Park; Seon-Kyu Kim; Mi-Aie Hwang; Jungwoon Lee; Mi-Jung Kang; Jae-Eun Byun; Joo-Young Im; Minho Kang; Kyung Chan Park; Young Il Yeom; Seon-Young Kim; Haiyoung Jung; Dae-Hyuk Kweon; Jae-Ho Cheong; Misun Won
Journal:  J Exp Clin Cancer Res       Date:  2022-06-29

Review 2.  Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.

Authors:  Masahiro Sasahara; Mitsuro Kanda; Yasuhiro Kodera
Journal:  Histol Histopathol       Date:  2021-03-09       Impact factor: 2.303

3.  SYT12 plays a critical role in oral cancer and may be a novel therapeutic target.

Authors:  Keitaro Eizuka; Dai Nakashima; Noritoshi Oka; Sho Wagai; Toshikazu Takahara; Tomoaki Saito; Kazuyuki Koike; Atsushi Kasamatsu; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  J Cancer       Date:  2019-08-27       Impact factor: 4.207

4.  Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells.

Authors:  Qin Li; Shun Zhang; Miao Hu; Ming Xu; Xiaohua Jiang
Journal:  Int J Mol Med       Date:  2019-11-26       Impact factor: 4.101

5.  Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer.

Authors:  Takahiro Ichikawa; Masahiro Shibata; Takahiro Inaishi; Ikumi Soeda; Mitsuro Kanda; Masamichi Hayashi; Yuko Takano; Dai Takeuchi; Nobuyuki Tsunoda; Yasuhiro Kodera; Toyone Kikumori
Journal:  Curr Oncol       Date:  2021-10-12       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.